Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Well-known risk factors for atherosclerosis include hypercholesterolaemia, hypertension, diabetes, and smoking. These conditions are associated with endothelial dysfunction, which itself is associated with reduced endothelial generation of nitric oxide (NO). This is an overview of the implications of NO generation in atherosclerosis and of the potential therapeutic benefit of drugs which donate NO, such as organic nitrates, nicorandil, and sydnonimines, or those which increase the availability of endogenous NO, such as statins, angiotensin-converting enzyme inhibitors, L-arginine, and tetrahydrobiopterin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 1×
“Numerous studies from various parts of the world have clearly established that C-reactive protein predicts future risk for cardiovascular disease in apparently healthy persons, independently of established risk factors in the majority of studies.(75,76) These studies clearly support a role of C-reactive protein in ath…”
BackgroundEndothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Role of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., & Münzel, T. (2001) · Circulation · doi:10.1161/hc4601.099485 · Cited by 1,961
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773 · cited 1×
“2% mortality in the placebo and ISDNþ hydralazine groups, respectively) among 1050 black patients with advanced heart failure (NYHA Class III or IV).(126) In contrast, in the ISIS-4 (Fourth International Study of Infarct Survival) placebo-controlled study, there was no significant reduction in 5 week mortality in pati…”
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Endothelial Function: A Critical Determinant in Atherosclerosis?
Landmesser, U., Hornig, B., & Drexler, H. (2004) · Circulation · doi:10.1161/01.cir.0000129501.88485.1f · Cited by 851
Mollnau, H., Wendt, M., Szöcs, K., Lassègue, B., Schulz, E., Oelze, M., Li, H., Bodenschatz, M., August, M., Kleschyov, A. L., et al. (2002) · Circulation Research · doi:10.1161/01.res.0000012569.55432.02 · Cited by 676
White, C. R., Darley-Usmar, V, Berrington, W. R., McAdams, M., Gore, J. Z., Thompson, J. A., Parks, D. A., Tarpey, M. M., & Freeman, B. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8745 · Cited by 367 · cited 1×
“Another potential vascular source of superoxide anion is xanthine oxidase (XO).(68,69) In patients with coronary disease, increased activity of coronary and endotheliumbound XO activity has recently been observed.”
Background
Cited by
Copper, oxidative stress, and human health
Uriu-Adams, J. Y., & Keen, C. L. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.015 · Cited by 975
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Recent developments in nitric oxide donor drugs
Miller, M. R., & Megson, I. L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707224 · Cited by 628
Role of insulin resistance in endothelial dysfunction
Muniyappa, R., & Sowers, J. R. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9229-1 · Cited by 539
“In addition to decreasing vascular tone, NO decreases expression of vascular cell adhesion molecules, attenuates production of pro-inflammatory cytokines, decreases leukocyte recruitment, inhibits VSMC proliferation, opposes apoptosis, attenuates platelet aggregation, and reduces monocyte adhesion to the vascular wall…”
Linking endothelial dysfunction with endothelial cell activation
Liao, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66843 · Cited by 456
Metadata
- Authors
- Herman, A. G., & Moncada, S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-23
- Volume
- 26
- Issue
- 19
- Pages
- 1945-1955
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2100657323
- Cited by
- 149
- References
- 13
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. https://app.cochat.ai/papers/10.1093/eurheartj/ehi333
- The paper
- Herman, A. G., & Moncada, S. (2005). Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.